Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus PHENETRON.
HISTAFED vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine